Speaker: Pierluigi Porcu

0:02:46

Challenges in diagnosing and treating CTCL

0:04:22

Promising treatments in CTCL

0:02:31

MAVORIC trial: mogamulizumab for R/R CTC

0:03:09

Improved understanding of CTCL disease biology

0:02:49

Exciting research in CTCL: genomics, the tumor microenvironment and the potential role of MRD

0:05:21

HRQoL in patients with R/R CTCL treated with lacutamab in the TELLOMAK trial

0:03:46

The current standard of care for CTCL

0:03:00

The current SOC in CTCL: skin-directed therapy, systemic therapy & clinical challenges

0:02:12

Pre-clinical activity of tipifarnib in CTCL

0:01:15

Hello TELLOMAK: new trial for T-cell lymphoma

0:01:42

New therapeutic directions in CTCL

0:03:18

Lacutamab in patients with advanced mycosis fungoides: results from the TELLOMAK trial

0:01:47

Oral nanatinostat and valganciclovir for EBV-associated lymphomas

0:01:35

Long-term outcomes for patients with PTCL: 10-year follow-up analysis

0:04:17

Nanatinostat and valganciclovir for EBV-associated lymphoma

0:02:27

The current standard of care for patients with PTCL

0:01:29

Current treatment landscape & unmet needs in cutaneous T-cell lymphoma: quality of life

0:05:22

#UniteToPrevent - Andre Goy, MD

0:01:15

Insights into the treatment of peripheral T-cell lymphomas and the role of autologous transplant

0:02:05

EBV-lymphoma treatments on the horizon

0:00:48

Horizon scan of T-cell lymphoma therapy

0:02:41

Improved outcomes in PTCL with the use of novel agents and transplantation

0:32:29

Keynote speaker: Understanding the monitoring and safety of IBD medications and biologics

0:02:04

IMC-001: preliminary results of novel PD-L1 inhibitor for R/R extranodal NK/T cell lymphoma